Striatal levels of MOR binding and μ-immunoreactivity were reduced in PD rats (83) and in MPTP-lesioned macaques treated with L-DOPA (80), as well as in PD patients undergoing chronic L-DOPA therapy (84). The gene discussed is OPRM1; the disease is Parkinson disease.